利格列汀联合二甲双胍治疗新诊断T2DM患者的临床疗效及安全性

Clinical Efficacy and Safety of Linagliptin Combined with Metformin in the Treatment of Newly Diagnosed Patients with T2DM

目的探讨利格列汀联合二甲双胍治疗新诊断T2DM患者的临床疗效及安全性。方法选取该院2017年6月—2019年6月收治的80例T2DM患者为研究对象,采用随机数字表法分为干预组和对照组,各40例,两组患者均常规给予饮食指导、运动指导,对照组患者仅给予二甲双胍口服治疗,干预组在对照组基础上给予利格列汀口服治疗,比较两组患者临床疗效、血糖指标、HOMA-β、HOMA-IR、血清炎症因子水平。结果干预组总有效率明显高于对照组,差异有统计学意义(P<0.05);干预组血糖指标、HOMA-IR、血清炎症因子水平明显低于对照组,HOMA-β明显高于对照组,差异有统计学意义(P<0.05)。结论T2DM患者采用利格列汀联合二甲双胍治疗,可提高降糖效果,且安全性高,值得临床推广。

Objective To investigate the clinical efficacy and safety of linagliptin combined with metformin in the treatment of newly diagnosed T2DM patients.Methods 80 T2DM patients admitted to the hospital from June 2017 to June 2019 were enrolled in the study.They were divided into intervention group and control group by random number table method.The two groups were routinely given dietary guidance and exercise.According to the guidance,the patients in the control group were treated with metformin only.The intervention group was treated with linagliptin orally.The clinical efficacy,blood glucose index,HOMA-β,HOMA-IR and serum inflammatory factors were compared between the two groups.Results The total effective rate of the intervention group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The blood glucose index,HOMA-IR and serum inflammatory factor levels in the intervention group were significantly lower than those in the control group,and HOMA-βwas significantly higher than the control group.The difference was statistically significant(P<0.05).Conclusion T2DM patients treated with linagliptin combined with metformin can improve the hypoglycemic effect,and it is safe and worthy of clinical promotion.